Acute rejection in a highly sensitized lung transplant recipient with pre-formed donor-directed anti-HLA class II antibodies: role of bortezomib therapy.
Department of Pharmacy Services, University of Michigan Health Systems, Ann Arbor, Michigan, USA.
Linda J
LJ
Stuckey
Malek
M
Kamoun
Anish
A
Wadhwa
Millie
M
Samaniego
Cathy
C
Bartos
Jennifer
J
Berry
Raja
R
Mahidhara
Andrew C
AC
Chang
Kevin M
KM
Chan
D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004359:Drug Therapy, Combination; D005260:Female; D015234:HLA-A Antigens / Q000276:immunology; D015235:HLA-B Antigens / Q000276:immunology; D006681:HLA-D Antigens / Q000276:immunology*; D006684:HLA-DR Antigens / Q000276:immunology; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood* / Q000187:drug effects; D017563:Lung Diseases, Interstitial / Q000601:surgery*; D016040:Lung Transplantation / Q000276:immunology*; D008875:Middle Aged; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*
D001897:Boronic Acids; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D015395:Histocompatibility Antigens Class I; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib